Table 4.
A comparison of the concentrations found in the current study compared with package inserts provided with oral contraceptives
| Cycle_Day | 1_1 | 1_6 | 1_21 | 3_21 | 6_21 | 9_21 | 13_21 | |
|---|---|---|---|---|---|---|---|---|
| Aviane (45) | EE (0.02 mg) average Cmax, pg/mL | 62 ± 20.5 | 76.7 ± 29.9 | 82.3 ± 33.2 | ||||
| Zarah (46) | EE (0.03 mg) average Cmax, pg/mL | 53.5 ± 23 | 92.1 ± 32.2 | 99.1 ± 44.6 | 87 ± 37.4 | 90.5 ± 40.7 | ||
| Current study | EE (0.02 mg) average Cmax, pg/mL | 59.6 ± 23.1 (n = 9) | ||||||
| EE (0.03 mg) average Cmax, pg/mL | 49.7 ± 36.0 (n = 4) | |||||||
| EE (0.035 mg) Cmax, pg/mL | 50.38 (n = 1) | |||||||
| Aviane (45) | Levonorgestrel (0.1 mg) average Cmax, ng/mL | 2.75 ± 0.88 | 4.52 ± 4.52 | 6 ± 2.65 | ||||
| Kuhnz et al. (28) | Levonorgestrel (0.15 mg) average concentration, ng/mL | 1.4 ± 0.5 | 1.7 ± 0.4 | |||||
| Zarah (46) | Drospirenone (3 mg) average Cmax, ng/mL | 36.9 ± 4.8 | 87.5 ± 51.6 | 84.2 ± 16.0 | 81.3 ± 15.4 | 78.7 ± 14.2 | ||
| Back et al. (27) | Norethindrone/NA concentration, ng/mL | 4.7 ± 1 | ||||||
| Current study | Drospirenone (3 mg) Cmax, ng/mL | 28.8 (n = 1) | ||||||
| Levonorgestrel average (0.1–1.5 mg) Cmax, ng/mL | 7.3 ± 7.7 (n = 3) | |||||||
| Norethindrone/NA (0.4–1.5 mg) Cmax, ng/mL | 7.9 ± 7.6 (n = 10) | |||||||
Data are presented as means ± SD. Cycle_Day corresponds to the time point of interest where the first number is the current treatment cycle and the second number is the day of the treatment cycle. Cmax, maximum concentration; EE, ethinyl estradiol; NA, norethindrone acetate.